November 29th 2023
The sNDA is supported by positive data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials.
November 28th 2023
The FDA’s PDUFA target date is May 25, 2024.
November 22nd 2023
One notable change: CVS Caremark has removed the Humira biosimilar Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
November 20th 2023
Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.
November 16th 2023
There are currently no FDA-approved therapies for the rare, genetic disease.
2 Clarke Drive Cranbury, NJ 08512